First-in-Class Immuno-Oncology Drug APG157DS Repolarizes Innate Immune Cells and Induces Durable Remission in a Syngeneic Glioblastoma Model
International Journal of Molecular Sciences · 27.07.2026 · 27 (15) · 6687
DOI: 10.3390/ijms27156687 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 27.07.2026. Verfasst von Shubhasmita Mohapatra und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, The College of Staten Island (CUNY), Staten Island, NY 10314, USA. Hauptthemen laut MEDLINE: Glioblastoma, Immunity, Innate, Brain Neoplasms. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIBIB NIH HHS, NIH HHS.
Abstract (Originalsprache)
APG157DS is a multi-component investigational drug which is currently the subject of multiple cancer trials. It has shown promising efficacy in patients with head and neck cancer. We report its immuno-modulatory effect in a syngeneic mouse model of glioblastoma (GBM). Long-term treatment with APG157DS led to durable tumor remission in 50% of mice, while all vehicle-treated mice reached humane endpoints within 42 days. Mechanistically, the drug induced selective repolarization of tumor-associated macrophages (TAMs) from an immunosuppressive Arg1high/iNOSlow phenotype to a tumoricidal Arg1low/iNOShigh state, accompanied by increased intratumoral recruitment of activated (NKp46+) natural killer cells and CD8+ cytotoxic T-cells. APG157DS also suppressed vascular endothelial growth factor (VEGF) and Hypoxia-inducible factor 1-alpha (HIF-1α) expression in tumors, further impairing tumor growth. Notably, APG157DS did not elicit off-target macrophage activation in peripheral tissues such as the spleen, highlighting its selective immune targeting. These findings provide a mechanistic rationale for further clinical development of APG157DS in GBM and potentially other immune-evasive cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, The College of Staten Island (CUNY), Staten Island, NY 10314, USA.
- Doctoral Program in Biochemistry, The College of Staten Island (CUNY), New York, NY 10314, USA.
- Department of Radiology, Bernard and Irene Schwartz Center for Biomedical Imaging & Center for Advanced Imaging Innovation and Research and Preclinical Imaging, Division for Advanced Research Technologies, New York Univ…
- Aveta Biomics, Inc., 110 Great Road, Suite 302, Bedford, MA 01730, USA.
- Center for Developmental Neuroscience, The College of Staten Island (CUNY), Staten Island, NY 10314, USA.
ORCID-Profile: Adrian Guerrero, Neha Rahman, Lauren O'Donnell, Probal Banerjee
Förderung
- NCI NIH HHS
- NIBIB NIH HHS
- NIH HHS
- Aveta Biomics, Inc.
- NYU Grossman School of Medicine Preclinical Imaging Laboratory
- the Laura and Isaac Perlmutter Cancer Center Support Grant
- the NIBIB Biomedical Technology Resource Center Grant
Zitieren
APA
Mohapatra, S., Guerrero, A., Rahman, N., Markovic, S., O'Donnell, L., Wadghiri, Y. Z., Zaman, K. T., Avila, L., Mehta, P., & Banerjee, P. (2026). First-in-Class Immuno-Oncology Drug APG157DS Repolarizes Innate Immune Cells and Induces Durable Remission in a Syngeneic Glioblastoma Model. International Journal of Molecular Sciences, 27(15), 6687. https://doi.org/10.3390/ijms27156687
Vancouver
Mohapatra S, Guerrero A, Rahman N, Markovic S, O'Donnell L, Wadghiri YZ, et al. First-in-Class Immuno-Oncology Drug APG157DS Repolarizes Innate Immune Cells and Induces Durable Remission in a Syngeneic Glioblastoma Model. International Journal of Molecular Sciences. 2026;27(15):6687. doi:10.3390/ijms27156687
BibTeX
@article{Mohapatra2026,
author = {Mohapatra, Shubhasmita and Guerrero, Adrian and Rahman, Neha and Markovic, Stefan and O'Donnell, Lauren and Wadghiri, Youssef Zaim and Zaman, Khondoker Takia and Avila, Luis and Mehta, Parag and Banerjee, Probal},
title = {First-in-Class Immuno-Oncology Drug APG157DS Repolarizes Innate Immune Cells and Induces Durable Remission in a Syngeneic Glioblastoma Model},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {15},
pages = {6687},
doi = {10.3390/ijms27156687}
}
EUVIMED